AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7271345 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 g in operating room plus 3,578 mg average during the next three days)
Number of subjects: 114
Study 7271345 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 114
Study 7271345 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 114
Study 30246369 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance-based messages (images of skin cancer, hyperpigmentation, wrinkles)
Number of subjects: 137
Study 30246369 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance-based messages
Number of subjects: 137
Study 27550954 — intervention group
Group type: COMPARATOR
Intervention: Crushed immediate-release oxycodone 40 mg
Number of subjects: 0
Study 27550954 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed ALO-02 40 mg/4.8 mg
Number of subjects: 0
Study 27550954 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed ALO-02 60 mg/7.2 mg
Number of subjects: 0
Study 27550954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact ALO-02 60 mg/7.2 mg
Number of subjects: 0
Study 27550954 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed ALO-02 (crushed or intact)
Number of subjects: 0
Study 26093827 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (DEFR) administered BID (40 mg/kg)
Number of subjects: 8
Study 26093827 — intervention group
Group type: COMPARATOR
Intervention: Deferasirox (DEFR) administered once daily (30 or 40 mg/kg)
Number of subjects: 8
Study 24140268 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus aflibercept
Number of subjects: 0
Study 24140268 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 0
Study 22686074 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medicine (IM) treatment for diabetic nephropathy
Number of subjects: 170
Study 20151768 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera) titrated once weekly
Number of subjects: 107
Study 20151768 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera) titrated twice weekly
Number of subjects: 107
Study 18052694 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy-aided scaling and root planing (SRP)
Number of subjects: 24
Study 18052694 — intervention group
Group type: COMPARATOR
Intervention: SRP alone (control)
Number of subjects: 24
Study 16222890 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg tamsulosin once daily orally (n = 40)
Number of subjects: 76
Study 16222890 — intervention group
Group type: COMPARATOR
Intervention: 10 mg alfuzosin once daily orally (n = 36)
Number of subjects: 76
Study 11507926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hexametaphosphate dentifrice
Number of subjects: 96
Study 11507926 — intervention group
Group type: COMPARATOR
Intervention: High-abrasive dentifrice
Number of subjects: 96
Study 11507926 — intervention group
Group type: COMPARATOR
Intervention: Marketed control dentifrice
Number of subjects: 96
Study 10102945 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d., clarithromycin 500 mg b.d., amoxycillin 1 g b.d.
Number of subjects: 278
Study 10102945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., amoxycillin 1 g b.d.
Number of subjects: 278
Study 10102945 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.d., clarithromycin 500 mg b.d., amoxycillin 1 g b.d.
Number of subjects: 278
Study 10102945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d., tetracycline 500 mg t.d.s., tinidazole 500 mg b.d.
Number of subjects: 278
Study 7757313 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipyrine powder (1,050 mg)
Number of subjects: 12
Study 7757313 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipyrine capsule (1,050 mg)
Number of subjects: 12
Study 7757313 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipyrine powder and capsule formulations
Number of subjects: 12
Study 7757313 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipyrine capsule formulation
Number of subjects: 12
Study 2148194 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 228
Study 2148194 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 228
Study 37697 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopimozide (average optimum daily dose of 13.95 mg)
Number of subjects: 40
Study 37697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31232917 — intervention group
Group type: EXPERIMENTAL
Intervention: MLH1-negative circulating tumor cells
Number of subjects: 32
Study 31232917 — intervention group
Group type: EXPERIMENTAL
Intervention: Total circulating tumor cells (CTCs)
Number of subjects: 32
Study 31232917 — intervention group
Group type: EXPERIMENTAL
Intervention: MLH1-negative CTCs
Number of subjects: 32
Study 31232917 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal markers-expressing CTCs
Number of subjects: 32
Study 28381198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor combined with aspirin
Number of subjects: 952
Study 28381198 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel combined with aspirin
Number of subjects: 952
Study 25471821 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making with more involvement than desired by the patient
Number of subjects: 445
Study 25471821 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisions made with clinicians whose decision-making style preference was for more active involvement than the patient preference
Number of subjects: 445
Study 23851776 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel applied directly for 24 hours
Number of subjects: 129
Study 23851776 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel applied directly for 48 hours
Number of subjects: 129
Study 23851776 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel kept in a glove finger for 24 hours
Number of subjects: 129
Study 23851776 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel kept in a glove finger for 48 hours
Number of subjects: 129
Study 21737787 — intervention group
Group type: EXPERIMENTAL
Intervention: 1×10(5) cells/kg of mobilized autologous CD34+ cells
Number of subjects: 167
Study 21737787 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volume of diluent)
Number of subjects: 167
Study 19929767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator‐induced hyperinflation using pressure support ventilation in sidelying
Number of subjects: 30
Study 19929767 — intervention group
Group type: COMPARATOR
Intervention: Sidelying
Number of subjects: 30
Study 16738150 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary overlap repair
Number of subjects: 64
Study 16738150 — intervention group
Group type: COMPARATOR
Intervention: End-to-end repair
Number of subjects: 64
Study 15129073 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-Horizon (CD-H)
Number of subjects: 127
Study 15129073 — intervention group
Group type: EXPERIMENTAL
Intervention: Moss Miami (MM)
Number of subjects: 127
Study 15129073 — intervention group
Group type: EXPERIMENTAL
Intervention: TSRH
Number of subjects: 127
Study 15129073 — intervention group
Group type: EXPERIMENTAL
Intervention: ISOLA
Number of subjects: 127
Study 11124134 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride (Intralipid 20%, 1.5 ml/min) and heparin (bolus: 200 IU; constant infusion rate: 0.2 IU.kg(‐1).min(‐1))
Number of subjects: 10
Study 11124134 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 10
Study 9767201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine
Number of subjects: 0
Study 9767201 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 0
Study 10381989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium with beta-agonists
Number of subjects: 1377
Study 2239170 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (GAGPS)
Number of subjects: 31
Study 2239170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 408145 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloric acid
Number of subjects: 15
Study 408145 — intervention group
Group type: COMPARATOR
Intervention: Protein-rich meal
Number of subjects: 15
Study 30232824 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon (PEB)
Number of subjects: 88
Study 30232824 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 88
Study 28194595 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-Balloon Colonoscopy (DBC)
Number of subjects: 18
Study 28194595 — intervention group
Group type: COMPARATOR
Intervention: Conventional Colonoscopy (CC)
Number of subjects: 18
Study 26307622 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexposure prophylaxis (PEP) for consensual sexual activity
Number of subjects: 3200
Study 26307622 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods
Number of subjects: 3200
Study 26307622 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined methods
Number of subjects: 3200
Study 26307622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP)
Number of subjects: 3200
Study 24074299 — intervention group
Group type: EXPERIMENTAL
Intervention: Online psychological treatment
Number of subjects: 1000
Study 24074299 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 1000
Study 22041670 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant preservation (RP) group
Number of subjects: 70
Study 22041670 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 19780352 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF fluoridated Ca‐free water
Number of subjects: 60
Study 19780352 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturally fluoridated hard water
Number of subjects: 60
Study 19780352 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificially fluoridated soft water
Number of subjects: 60
Study 16762124 — intervention group
Group type: EXPERIMENTAL
Intervention: Course in motivational interviewing
Number of subjects: 3
Study 16762124 — intervention group
Group type: COMPARATOR
Intervention: Control group (no course)
Number of subjects: 3
Study 15574072 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training for quadriceps and hamstring muscles
Number of subjects: 22
Study 15574072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no strength training)
Number of subjects: 22
Study 11318061 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-right/down-left mapping with left response initiating action
Number of subjects: 0
Study 11318061 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-right/down-left mapping with right response initiating action
Number of subjects: 0
Study 11318061 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-right/down-left mapping with both keypresses
Number of subjects: 0
Study 11318061 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-right/down-left mapping with both spoken location names
Number of subjects: 0
Study 11318061 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-right/down-left mapping with one spoken location name and one keypress
Number of subjects: 0
Study 9463667 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 287
Study 9463667 — intervention group
Group type: COMPARATOR
Intervention: Oral iron treatment
Number of subjects: 287
Study 9463667 — intervention group
Group type: COMPARATOR
Intervention: Malaria chemoprophylaxis after discharge
Number of subjects: 287
Study 8193499 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based formula (Isomil)
Number of subjects: 76
Study 8193499 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk formula (SMA)
Number of subjects: 76
Study 8193499 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study 2574555 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine, 60 mg bid
Number of subjects: 37
Study 2574555 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 25 mg qid
Number of subjects: 37
Study 2574555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 30919459 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu380Ag
Number of subjects: 600
Study 30117448 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular stimulation (swinging back to front)
Number of subjects: 240
Study 30117448 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vestibular stimulation)
Number of subjects: 240
Study 26188234 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring group (TG)
Number of subjects: 105
Study 26188234 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 105
Study 23767790 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk
Number of subjects: 18
Study 23767790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21269305 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (MINO) for 4 weeks
Number of subjects: 0
Study 21269305 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (RXM) for 4 weeks
Number of subjects: 0
Study 21269305 — intervention group
Group type: EXPERIMENTAL
Intervention: Faropenem (FRPM) for 4 weeks
Number of subjects: 0
Study 21269305 — intervention group
Group type: COMPARATOR
Intervention: Control (no oral antibiotics for 4 weeks)
Number of subjects: 0
Study 18185995 — intervention group
Group type: EXPERIMENTAL
Intervention: KEEP (Keeping Foster Parents Trained and Supported) based on Multidimensional Treatment Foster Care (MTFC)
Number of subjects: 700
Study 18185995 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 700
Study 16877984 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg) combined with IV propofol (0.5 mg/kg)
Number of subjects: 54
Study 16877984 — intervention group
Group type: COMPARATOR
Intervention: IV propofol alone
Number of subjects: 54
Study 16877984 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam combined with IV propofol
Number of subjects: 54
Study 16877984 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 54
Study 12780361 — intervention group
Group type: EXPERIMENTAL
Intervention: High winning expectancies
Number of subjects: 34
Study 12780361 — intervention group
Group type: COMPARATOR
Intervention: Low winning expectancies
Number of subjects: 34
Study 10966534 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Dimer levels measured at admission to the ED
Number of subjects: 257
Study 10966534 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Dimer level >500 microg/L
Number of subjects: 257
Study 10966534 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen levels measured at admission to the ED
Number of subjects: 257
Study 10966534 — intervention group
Group type: EXPERIMENTAL
Intervention: Other hemostatic markers (thrombin‐antithrombin complexes, prothrombin fragment 1+2, activated factor VII)
Number of subjects: 257
Study 8941062 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/d MPA plus 0.625 mg/d conjugated estrogens (group A: 31 patients)
Number of subjects: 59
Study 8941062 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d estrone sulfate (group B: 28 patients)
Number of subjects: 59
Study 1609752 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 mg Zn/d
Number of subjects: 11
Study 1609752 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg Zn/d
Number of subjects: 11
Study 1609752 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.4 mg Zn/d
Number of subjects: 11
Study 1609752 — intervention group
Group type: COMPARATOR
Intervention: 10.4 mg Zn/d
Number of subjects: 11
Study 4001840 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro challenge with foods or food antigens on mucosal specimens
Number of subjects: 15
Study 4001840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric food challenge
Number of subjects: 15
Study 4001840 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro challenge
Number of subjects: 15
Study 4001840 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioallergosorbent and skin tests
Number of subjects: 15
Study 31468596 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene 25 mg
Number of subjects: 44
Study 31468596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 29167971 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide-SC 20 μg
Number of subjects: 222
Study 29167971 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide-SC 40 μg
Number of subjects: 222
Study 29167971 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide-SC 80 μg
Number of subjects: 222
Study 29167971 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous teriparatide 20 μg
Number of subjects: 222
Study 29167971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 26201835 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA (400 U)
Number of subjects: 259
Study 26201835 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 259
Study 23756850 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (prednisolone + lamivudine)
Number of subjects: 46
Study 23756850 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (prednisolone)
Number of subjects: 46
Study 22040285 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) intervention consisting of three 2-hr group sessions scheduled during a single week.
Number of subjects: 133
Study 22040285 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 133
Study 20227241 — intervention group
Group type: EXPERIMENTAL
Intervention: web‐based therapist‐assisted cognitive behavioral treatment (web‐CBT)
Number of subjects: 58
Study 20227241 — intervention group
Group type: COMPARATOR
Intervention: waiting‐list control
Number of subjects: 58
Study 17765381 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of dimenhydrinate
Number of subjects: 12
Study 17765381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15804686 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete smoking cessation (abstainers)
Number of subjects: 220
Study 15804686 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking reduction (reducers)
Number of subjects: 220
Study 15804686 — intervention group
Group type: COMPARATOR
Intervention: Continuation of usual smoking (continuing smokers)
Number of subjects: 220
Study 12512792 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment protocol as defined by consensus among acupuncture trainers
Number of subjects: 14
Study 10329342 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 continuous minutes of brisk walking
Number of subjects: 32
Study 10329342 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 10‐minute bouts of brisk walking
Number of subjects: 32
Study 10329342 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of brisk walking in any combination of bouts (minimum 5 minutes each)
Number of subjects: 32
Study 7866989 — intervention group
Group type: EXPERIMENTAL
Intervention: HMFG1 (IgG1 radiolabeled anti-mucin mAb)
Number of subjects: 29
Study 7866989 — intervention group
Group type: COMPARATOR
Intervention: Control (4D513 isotype-matched control)
Number of subjects: 29
Study 1742749 — intervention group
Group type: EXPERIMENTAL
Intervention: L-threonine 4.5 g/day
Number of subjects: 18
Study 1742749 — intervention group
Group type: EXPERIMENTAL
Intervention: L-threonine 6.0 g/day
Number of subjects: 18
Study 1742749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6891929 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 5 mg b.d. (P)
Number of subjects: 204
Study 6891929 — intervention group
Group type: COMPARATOR
Intervention: Ovarian irradiation (O)
Number of subjects: 204
Study 6891929 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 10 mg b.d. (T)
Number of subjects: 204
Study 30724701 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted Jacket (WJ)
Number of subjects: 29
Study 30724701 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentrically Loaded Dumbbell (LDB)
Number of subjects: 29
Study 30724701 — intervention group
Group type: COMPARATOR
Intervention: Countermovement Jump (CMJ)
Number of subjects: 29
Study 28142296 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsule
Number of subjects: 60
Study 28142296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27065056 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12-receptor specific assay (ADPtest HS)
Number of subjects: 400
Study 27065056 — intervention group
Group type: COMPARATOR
Intervention: Standard ADP assay (ADPtest)
Number of subjects: 400
Study 24685414 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Regimen + individualized homeopathic medicine (SR + H)
Number of subjects: 120
Study 24685414 — intervention group
Group type: COMPARATOR
Intervention: Standard Regimen + identical placebo (SR + P)
Number of subjects: 120
Study 22515945 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 15
Study 22515945 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15
Study 22515945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water-induced DNIC
Number of subjects: 15
Study 22515945 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tDCS and DNIC
Number of subjects: 15
Study 19039231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy to maintain strict normoglycemia (below 110 mg/dl)
Number of subjects: 0
Study 19039231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0
Study 19039231 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict blood glucose control with intensive insulin therapy
Number of subjects: 0
Study 19039231 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict blood glucose control
Number of subjects: 0
Study 18088216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) delivered in school or clinic settings by trained clinicians
Number of subjects: 700